

Amendment to the Claims

Listing of Claims:

1 1. (Previously presented) A compound having the formula:



2 wherein

3 Ab is an antibody;

4 G is an intact glycosyl linking group covalently joining Ab to L;

5 L is a bond or a spacer moiety covalently joining G to T; and

6 T is a toxin, wherein

7 said spacer moiety is a member selected from substituted or unsubstituted alkyl, substituted or
8 unsubstituted heteroalkyl and substituted or unsubstituted aryl moieties.

1 2. (Canceled)

1 3. (Previously presented) The compound according to claim 1, wherein said spacer moiety
2 comprises a poly(ethylene glycol) moiety.

1 4. (Previously presented) A compound having the formula:




2 wherein

3 Ab is an antibody;

4 G is an intact glycosyl linking group covalently joining Ab to L;

5 L is a spacer moiety covalently joining G to T; and

6 T is a toxin, wherein L has the formula:



7 wherein

8 L¹ is a bond or a linker moiety covalently joining G to A;


9 A is an amplifier moiety; and

10 L² is a bond or a spacer moiety covalently adjoining A to T.

11 5. (Original) The compound according to claim 4, wherein said amplifier moiety is a polyamine
12 moiety.

1 6. (Original) The compound according to claim 5, wherein said polyamine moiety is a dendrimer.

1 7. (Previously presented) The compound according to claim 4, having the formula:



2

3 wherein

4 PEG is a straight- or branched-chain poly(ethylene glycol);

5 m is an integer from 1 to 6; and

6 n is an integer from 1 to 1,000.

1 8. (Previously presented) The compound according to claim 4, having the formula:




2 wherein

4 m is an integer from 1 to 6; and

5 n is an integer from 1 to 1,000.

1 9. (Previously presented) The compound according to claim 4, having the formula:




2 wherein

4 m is an integer from 1 to 6; and

5 n is an integer from 1 to 1,000.

1 10. (Currently amended) A compound having the formula:




2 wherein

4 X¹, X², X³, and X⁴ are linking groups and are members selected from the group consisting
5 of O, S, NH, (CH₂)_q-NH, NH-(CH₂)_q, NH-C(O)-O, O-C(O)-NH,
6 (CH₂)_q-NH-C(O)-O, O-C(O)-NH-(CH₂)_q, C(O)-O, O-C(O), (CH₂)_q-NH-C(O),
7 C(O)-NH-(CH₂)_q, NH-C(S), and C(S)-NH

8 and wherein


9 Ab is an antibody;
10 G is an intact glycosyl linking group covalently joining Ab to X¹ L;
11 T is a toxin;
12 A is an amplifier moiety;
13 Z is a bond cleaved by a metabolic/physiological process;
14 n is an integer from 1 to 1,000;
15 a is an integer from 1 to 10;
16 b is an integer from 1 to 10; and
17 q is and integer from 0 to 20.

1 11. (Currently amended) A compound having the formula:



3 wherein

4 at least one of R¹, R², R³, R⁴, R⁵, is :



6 wherein

7 Ab is an antibody;

8 G is an intact glycosyl linking group covalently joining Ab to Z¹ L;

9 T is a toxin;

10 r is an integer from 1 to 2,500;

11 A is an amplifier moiety;

12 Z¹ is selected from the group consisting of O, S, and NH;

13 Z² is selected from the group consisting of NH, and NH-(CH₂)_q;

14 and

15 X¹, X² and X³ are linking groups and are members selected from the group consisting of

16 O, S, NH, (CH₂)_q-NH, NH-(CH₂)_q, NH-C(O)-O, O-C(O)-NH,


17 (CH₂)_q-NH-C(O)-O, O-C(O)-NH-(CH₂)_q, C(O)-O, O-C(O), (CH₂)_q-NH-C(O),

18 C(O)-NH-(CH₂)_q, NH-C(S), and C(S)-NH

19 wherein

20 n is an integer from 1 to 1,000; and
21 q is an integer from 0 to 20.

1 12. (Currently amended) A compound having the formula:



8 X¹, X² and X⁴ are linking groups and are members selected from the group consisting of
9 O, S, NH, (CH₂)_q-NH, NH-(CH₂)_q, NH-C(O)-O, O-C(O)-NH,
10 (CH₂)_q-NH-C(O)-O, O-C(O)-NH-(CH₂)_q, C(O)-O, O-C(O), (CH₂)_q-NH-C(O),
11 C(O)-NH-(CH₂)_q, NH-C(S), and C(S)-NH

12 wherein

13 Ab is an antibody;

14 G is an intact glycosyl linking group covalently joining Ab to X¹ L;


T is a toxin;

A is an amplifier moiety;

n is an integer from 1 to 1,000; and


q is an integer from 0 to 20.

1 13. (Previously presented) The compound according to claim 12, having the formula:



7 n is an integer from 1 to 1,000.

1 14. (Withdrawn) A compound having the formula:



3 wherein

4 S is a nucleotide sugar


5 L is a bond or a spacer moiety covalently joining S to T; and

6 T is a toxin moiety.

1 15. (Withdrawn) The compound according to claim 14, wherein said spacer moiety is a member
2 selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl and substituted or
3 unsubstituted aryl moieties.

1 16. (Withdrawn) The compound according to claim 15, wherein said spacer moiety comprises a
2 poly(ethylene glycol) moiety.

1 17. (Withdrawn) The compound according to claim 14, wherein L has the formula:



2 wherein

4 L^1 is a bond or a spacer moiety covalently joining S to A;


5 A is an amplifier moiety; and

6 L^2 is a bond or a spacer moiety covalently joining A to T.

1 18. (Withdrawn) The compound according to claim 17, wherein said amplifier moiety is a polyamine
2 moiety.

1 19. (Withdrawn) The compound according to claim 18, wherein said polyamine moiety is a
2 dendrimer.

1 20. (Withdrawn) The compound according to claim 17, having the formula:



2 wherein

4 PEG is a straight- or branched-chain poly(ethylene glycol);

5 m is an integer from 1 to 6; and

6 n is an integer from 1 to 1,000.

1 21. (Withdrawn) The compound according to claim 17, having the formula:




2 wherein

4 m is an integer from 1 to 6; and

5 n is an integer from 1 to 1,000.

1 22. (Withdrawn) The compound according to claim 17, having the formula:




3 wherein

4 m is an integer from 1 to 6; and

5 n is an integer from 1 to 1,000.

1 23. (Withdrawn) The compound according to claim 22, having the formula:



2 wherein

3 X^1 , X^2 and X^3 are linking groups and are members selected from the group consisting of
4 O, S, $\text{NH}(\text{CH}_2)_q-\text{NH}$, $\text{NH}-(\text{CH}_2)_q$, $\text{NH}-\text{C}(\text{O})-\text{O}$, $\text{O}-\text{C}(\text{O})-\text{NH}$, $(\text{CH}_2)_q-\text{NH}-\text{C}(\text{O})-\text{O}$,
5 $\text{O}-\text{C}(\text{O})-\text{NH}-(\text{CH}_2)_q$, $\text{C}(\text{O})-\text{O}$, $\text{O}-\text{C}(\text{O})$, $(\text{CH}_2)_q-\text{NH}-\text{C}(\text{O})$, $\text{C}(\text{O})-\text{NH}-(\text{CH}_2)_q$,
6 $\text{NH}-\text{C}(\text{S})$, and $\text{C}(\text{S})-\text{NH}$

7 and wherein

8 A is an amplifier moiety;

9 Z is a bond cleaved by a metabolic/physiological process;


10 n is an integer from 1 to 1,000;

11 a is an integer from 1 to 10;

12 b is an integer from 1 to 10; and

13 q is an integer from 0 to 20.

1 24. (Withdrawn) The compound according to claim 14, having the formula:



2 wherein

3 X^1 , X^2 and X^3 are linking groups and are members selected from the group consisting of
4 O, S, $\text{NH}(\text{CH}_2)_q-\text{NH}$, $\text{NH}-(\text{CH}_2)_q$, $\text{NH}-\text{C}(\text{O})-\text{O}$, $\text{O}-\text{C}(\text{O})-\text{NH}$, $(\text{CH}_2)_q-\text{NH}-\text{C}(\text{O})-\text{O}$,
5 $\text{O}-\text{C}(\text{O})-\text{NH}-(\text{CH}_2)_q$, $\text{C}(\text{O})-\text{O}$, $\text{O}-\text{C}(\text{O})$, $(\text{CH}_2)_q-\text{NH}-\text{C}(\text{O})$, $\text{C}(\text{O})-\text{NH}-(\text{CH}_2)_q$,
6 $\text{NH}-\text{C}(\text{S})$, and $\text{C}(\text{S})-\text{NH}$

7 wherein

8 q is an integer from 0 to 20.

1 25. (Withdrawn) The compound according to claim 24, having the formula:

2

